Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) posted its earnings results on Thursday. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.02, FiscalAI reports. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The firm had revenue of $58.57 million during the quarter, compared to analyst estimates of $81.79 million.
Aurinia Pharmaceuticals Stock Performance
NASDAQ:AUPH opened at $16.13 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.01 and a current ratio of 5.55. The company has a fifty day moving average of $15.94 and a two-hundred day moving average of $15.35. The stock has a market capitalization of $2.07 billion, a PE ratio of 7.43 and a beta of 1.42. Aurinia Pharmaceuticals has a fifty-two week low of $10.34 and a fifty-two week high of $19.25.
Insider Activity
In related news, CEO Kevin Tang bought 206,005 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were acquired at an average price of $15.28 per share, for a total transaction of $3,147,756.40. Following the completion of the transaction, the chief executive officer directly owned 13,044,106 shares in the company, valued at $199,313,939.68. This trade represents a 1.60% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have bought a total of 814,606 shares of company stock valued at $12,455,129 in the last quarter. 10.40% of the stock is owned by company insiders.
Institutional Investors Weigh In On Aurinia Pharmaceuticals
Analysts Set New Price Targets
A number of research analysts have weighed in on AUPH shares. Zacks Research cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings cut Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, May 15th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $17.33.
View Our Latest Report on Aurinia Pharmaceuticals
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.
The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Western Digital Stock Falls 12% Despite Beating Earnings Estimates
- One Comment on CVS’s Earnings Call Sent the Stock Tumbling
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
